Increased liver fat content and unfavorable glucose profiles in subjects without diabetes

Diabetes Technology and Therapeutics

Volumn 13, Issue 2, 2011, Pages 149-155

  Bian, Hua ^a   Yan, Hongmei ^a   Zeng, Mengsu ^a   Rao, Shengxiang ^a   Yao, Xiuzhong ^a   Zhou, Jian ^b   Jia, Weiping ^b   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; FAT; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID STORAGE; LIVER LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REFERENCE VALUE;

ADULT; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CHINA; CIRCADIAN RHYTHM; EARLY DIAGNOSIS; FATTY LIVER; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MICRODIALYSIS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PREDIABETIC STATE; TRIGLYCERIDES;

EID: 79551609294     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0101     Document Type: Article

References (30)

1. 149-155 1. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndorme. Hepatology 2003;37:917-923.
3. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
4. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, Dalle Grave R, Morpurgo PS, Tomasi F, Vitacolonna E: Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005;28:333-339.
5. Clark JM, Diehl AM, Brancati FL: Nonalcoholic fatty liver disease and the risk of type 2 diabetes in the United States [abstract]. Diabetes 2001;50:A38.
6. Meltzer AA, Everhart JE: Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans. Am J Epidemiol 1997;146:565-571.
7. Yan HM, Gao X, Liu M, Gu Q, Zhang B, Gao J, Zhao NQ: Study of the association between non-alcoholic fatty liver disease and metabolic syndrome [in Chinese]. Zhongguo Tang Niao Bing Za Zhi 2006;24:326-328.
8. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA: High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51:1889-1895. (Pubitemid 34564303)
9. Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004;53:2855-2860.
10. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK: NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009;104:861-867.
11. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y: Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007;22:1086-1091.
12. Nakanishi N, Suzuki K, Tatara K: Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004;27: 1427-1432. (Pubitemid 38679993)
13. Lee DH, Ha MH, Kim JH, Christiani DC, Gross MD, Steffes M, Blomhoff R, Jacobs DR Jr: Gamma-glutamyltransferase and diabetes-a 4 year follow-up study. Diabetologia 2003; 46:359-364.
14. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W: Reference values for continuous glucose monitoring in Chinese. Diabetes Care 2009;32:1188-1193.
15. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26: 3160-3167.
16. World Health Organization-International Society of Hypertension: Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183.
17. World Health Organization: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:1-253.
18. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults: Chinese guidelines on prevention and treatment of dyslipidemia in adults [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:390-419.
19. Mastrototaro JJ: The MiniMed continuous glucose monitoring system. Diabetes Technol Ther 2000;2(Suppl 1):S13-S18.
20. Gross TM, Mastrototaro JJ: Efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther 2000;2(Suppl 1):S19-S26.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412-419.
22. Reaven GM: Banting Lecture: role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
23. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-3028.
24. Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jä rvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-758.
25. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS: Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-2175.
26. Yki-Järvinen H: Action of insulin on glucose metabolism in vivo. Baillieres Clin Endocrinol Metab 1993;7:903-927.
27. Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J: Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006;29:1909-1914.
28. Kotronen A, Yki-Järvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
29. Unger RH: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-5165.
30. Meyer C, Dostou J, Nadkarni V, Gerich J: Effects of physiological hyperinsulinemia on systemic, renal and hepatic substrate metabolism. Am J Physiol 1998;275:F915-F921.